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Cutaneous melanoma is the fastest increasing cancer worldwide. Although several molecular abnormalities have been associ-
ated with melanoma progression, the underlying mechanisms are still largely unknown and few targeted therapies are under
evaluation. Here we show that the HOXB7/PBX2 dimer acts as a positive transcriptional regulator of the oncogenic microRNA-
221 and -222. In addition, demonstrating c-FOS as a direct target of miR-221&222, we identify a HOXB7/PBX2ﬁmiR-221&222
ﬁc-FOS regulatory link, whereby the abrogation of functional HOXB7/PBX2 dimers leads to reduced miR-221&222 transcrip-
tion and elevated c-FOS expression with consequent cell death. Taking advantage of the treatment with the peptide HXR9, an
antagonist of HOX/PBX dimerization, we recognize miR-221&222 as effectors of its action, in turn confirming the HXR9 effi-
cacy in the treatment of human melanoma malignancy, whilst sparing normal human melanocytes. Our findings, besides sug-
gesting the potential therapeutic of HXR9 or its derivatives in malignant melanoma, suggest the disruption of the HOXB7/
PBX2 complexes, miR-221&222 inhibition or even better their combination, as innovative therapeutic approaches.
Malignant melanoma is the most aggressive form of skin can-
cer whose incidence has more than tripled in the white popu-
lation during the last 20 years. Although surgical excision is
mostly a deﬁnitive treatment at the early stages of the dis-
ease, at present standard treatments are ineffective after met-
astatic dissemination and patients with advanced disease have
a grim prognosis, with a 5-year survival rate of less than
20%.1 The homeobox (HOX) genes are a family of homeodo-
main containing transcription factors that deﬁne the identity
of cells and tissues during early development.2 Most cases of
aberrant HOX gene expression include HOX genes that are
normally silenced in adult cells and re-expressed in a wide
variety of neoplasias suggesting the HOX family as another
class of oncofetal genes.3 A number of studies have shown
the contribution of some HOX genes in cancer. These
include HOXA5 and HOXA10, playing tumor suppressor
functions in breast carcinoma, or HOXC11 inducing S100b,
an established marker of melanoma progression.4–6 HOXB7
has been reported as a master regulator in the oncogenic hi-
erarchy.7 HOX proteins bind to DNA through a highly con-
served 60 amino acid sequence called the homeodomain. The
speciﬁcity and stability of HOX binding to DNA are achieved
when it forms complexes with cofactors such as PBX and
MEIS in humans. In previous studies, we demonstrated
HOXB7 constitutive expression in melanoma primary lesions
and cell lines whereby it is able to bind to the promoter and
activate the transcription of bFGF.8 Also, by using a domi-
nant-negative PBX mutant (PBXNT), we showed that
HOXB7 requires PBX as a co-factor for its oncogenic ac-
tivity.9 The HOX/PBX binding interaction, mediated
through a speciﬁc and highly conserved hydrophobic hexa-
peptide,10,11 strongly increases HOX/DNA afﬁnity. Synthetic
peptides mimicking this hexapeptide motif can interfere
with HOX/PBX binding, including the small cell permeable
peptide HXR9, which speciﬁcally antagonizes the interac-
tion between HOX and PBX interfering with the binding
of these proteins to the “HOX/PBX” DNA consensus sites.
This disruption in turn triggers apoptosis in cancer cells
both in vitro and in vivo.12 Considering the signiﬁcant role
played by HXR9 in renal, ovarian and non small cell lung
cancer (NSCLC) as well as in murine B16 melanoma
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cells,12–15 we investigated the effects of this novel peptide
in human melanoma cell lines.
Accumulating evidence suggests that the family of regula-
tory RNAs, so called micro RNAs (miRs), plays an important
role in various human cancers. MiRs are small non coding
RNAs (21–25 nucleotides) that bind to partially complemen-
tary sites in the 3’ untranslated regions of target genes regu-
lating gene expression mostly at post-transcriptional level.16
Among the most dysregulated microRNAs implicated in can-
cer are miR-221 and miR-222, whose expression is highly up-
regulated in a variety of solid tumors, including
melanoma.17,18 Besides being positive regulators of the cell
cycle, miR-221&222 play an anti-apoptotic role as several of
their mRNA targets are pro-apoptotic in nature. Thus, the
increased expression of these two miRs leads to enhanced
cell proliferation and survival.19 Based on our previous stud-
ies demonstrating the tumorigenic role of miR-221 and miR-
222 in melanoma development and progression,18 here we
demonstrate the transcriptional activating role of HOXB7/
PBX2 complex on these two micro RNAs and, in turn, miR-
221&222 direct targeting of c-FOS. These data were also con-
ﬁrmed by the HXR9 peptide, able to interfere with the HOX/
PBX dimerization, as a HXR9-dependent down-regulation of
both miR-221 and -222 followed by c-FOS and apoptosis
induction was observed. The potential value of the HOXB7/
PBX2!miR-221&222!c-FOS pathway suggests the disrup-
tion of the HOXB7/PBX2 complexes, miR-221&222 inhibi-
tion or their combination as innovative therapeutic
approaches in melanoma.
Material and Methods
Cell lines culture and transduction
Most of the human melanoma cell lines used in the current
study was stabilized from surgical specimens obtained from
primary or metastatic tumors at Istituto Nazionale Tumori in
Milan (Italy) (Supporting Information Table S1). Cell lines
were characterized for growth in soft agar and, whenever
possible, their metastatic potential was evaluated into athymic
nude mice.8,18 The A375 cell line was from the American
Type Tissue Collection (Rockville, MD) and its metastatic
variant A375M20 was kindly provided by Dr. R. Giavazzi (Ist.
M. Negri, Bergamo). The Mel888 cell line was kindly pro-
vided by Dr. R. Morgan (University of Surrey, Guildford,
UK). Normal human epidermal melanocytes from foreskin
were obtained from Promocell (Heidelberg, Germany).
The biopsy melanoma specimens used in this study were
obtained from the archives of the Human Pathology Section,
University of Palermo. Five cutaneous primary and ﬁve
lymph nodal metastatic samples were analyzed. Sampling and
handling of human tissue material was carried out in accord-
ance with the ethical principle of the Declaration of Helsinki.
The HOXB7 cDNA encompassing its complete coding
sequence was cloned into the expression vector pSG5. The
pSG5 empty vector was used as an internal control. Overex-
pression of miR-221&222 was obtained in melanoma cells by
using a lentiviral vector system, as reported.18 pMCEF-
BRAFV600E construct was kindly provided by Dr. R. Marais
(Institute of Cancer Research, London, UK). “Controls” are
always intended as empty vector-transduced cell lines.
Small-interfering RNA
HOXB7 and PBX2 were speciﬁcally silenced using small inter-
fering RNAs (IDT, Leuven, Belgium). Brieﬂy, 24 hr after plat-
ing, cells were transfected using Fugene HD (Promega,
Madison, WI) with Dsi-HOXB7 (three different sequences were
utilized: HSC.RNAI.N004502.12.1, HSC.RNAI.N004502.12.2,
and HSC.RNAI.N004502.12.3), Dsi-PBX2 (HSC.RNAI.N00
2586.12.1), or a Dsi-RNA scrambled control (Dsi-scr #64218
602) (ﬁnal concentration 100 nM). The levels of HOXB7 and
PBX2 mRNA and protein were analyzed 48 hr after transfec-
tion by qReal-time PCR and western blot. When indicated, cy-
cloheximide (CHX) (50 mg/mL) was added in Dsi-transfected
A375M cells and total protein extracts analyzed by Western
blot at the indicated time points. SiRNAs for c-FOS were obtai-
ned from Ambion Inc. from the Silencer Select siRNA range. A
negative control siRNA was used from the Ambion Silencer
siRNA Starter Kit (AM1640), and transfections were performed
using the siPORT NeoFX/Opti-MEM I transfection reagents,
also included in the kit, according to the manufacturer’s
instructions. Transfections were performed in a 96-well plate
using 0.8 mL siSPORT neoFx and 9.2 mL Opti-MEM I per well.
MicroRNA-221 and -222 silencing by antagomir treatment
Chemically modiﬁed antisense oligonucleotides (antagomiRs)
have been used to inhibit miR-221 and/or -222 expression in
vitro, as described.21
Chromatin Immunoprecipitation (ChIP) Assay
Cells (5 3 106) from A375M melanoma cell line were ﬁxed
in 1% formaldehyde for 10 min at room temperature. Cells
What’s new?
Cutaneous melanoma is the fastest increasing cancer worldwide. Although several molecular abnormalities have been associ-
ated with melanoma progression, the underlying mechanisms are still largely unknown. Here the authors show that the
HOXB7/PBX2 complex is a new transcriptional activator of the oncogenic microRNA-221 and 222 in melanoma inducing tumor
malignancy. The authors also identified c-FOS as a direct target of miR-221&222 whose repression causes reduced apoptosis.
The abrogation of HOXB7 and/or miR-221&222 or the disruption of HOXB7/PBX2 dimers by the peptide HXR9 might thus rep-
resent novel molecular approaches for advanced melanoma, an aggressive neoplasm refractory to traditional therapies.
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were washed with ice cold 13 PBS, scraped in 13 PBS plus
protease inhibitors and collected by centrifugation. Cell pel-
lets, resuspended in cell lysis buffer (50 mM Tris-HCl pH
8.0, 10 mM EDTA, 1% SDS) in presence of protease inhibi-
tors, were sonicated. DNA-protein complexes were immuno-
precipitated using 3 lg of anti-HOXB7 (Invitrogen Ltd.,
Paisley, Scotland UK), anti-PBX2 or, as an internal control,
the unrelated anti-DVL-1 (Santa Cruz Biotechnology, Santa
Cruz, CA). DNA-protein crosslinks were reversed by heating
at 65C overnight. The recovered DNAs were then PCR-
ampliﬁed with the following primer set: DIR 5’-CAGCATA-
CATGATTCCTTGTGA-3’ and REV 5’-CTTTGGTGTTTGA-
GATGTTTGG-3’, corresponding to (2352/11) region and
containing HOX/PBX BS1 at 2255; DIR 5’-CCCACCAA-
GAGCTAACCACA-3’ and REV 5’-TCGGACATGCAGCTA-
TACCA-3’ corresponding to (21786/21035) and containing
HOX/PBX BS2 at 21390. Two negative control regions
(2891/2698) and (21066/2902) were also ampliﬁed. A pos-
itive control of ampliﬁcation was carried out on input chro-
matin (preserved before immunoprecipitation) and a negative
one on DVL-1 (unrelated)-immunoprecipitated chromatin.
To conﬁrm the speciﬁcity of the immunoprecipitated prod-
ucts, GAPDH PCRs were also run.
Analysis of cell death and apoptosis detection
Cells received 40 mmol/L of HXR9, or the control peptide
CXR9 for 2 hr, and were harvested for subsequent analyses.
The assessment of cell viability was done using the MTS
assay (Promega, Madison, WI) or the lactose dehydrogenase
(LDH) cytotoxicity detection kit (Roche Molecular Biochemi-
cals) according to the manufacturer’s instructions. For the
sub-G0 PI staining assay, the cells were incubated in a buffer
containing 0.1% trisodium citrate, 9.65 mM NaCl, 0.1%
NP40, 5 mg/ml PI, and 1 mg/ml RNase A, at room tempera-
ture for 30 min. Fluorescence emission was measured by ﬂow
cytometry. Cells with a sub-G0 content were identiﬁed as ap-
optotic. Apoptosis level was also determined by using the
annexin V-FITC apoptosis detection kit as described by the
manufacturer (R&D Systems, Abingdon, UK). The caspase
inhibitor Z-VAD-fmk (R&D Systems, Abingdon, UK) was
used at a concentration of 200 mM for 1 hr before CXR9 or
HXR9 treatment.
In vivo assay
All the animal experiments were conducted in accordance
with the United Kingdom Co-ordinating Committee on Can-
cer Research (UKCCCR) guidelines for the Welfare of Ani-
mals in Experimental Neoplasia. The mice were kept in
positive pressure isolators in 12 hr light/dark cycles and food
and water were available ad libitum. Athymic nude mice
were inoculated subcutaneously with a suspension of 2.5 3
106 A375M cells in culture media (100 mL). Once tumors
reached volumes of approximately 100 mm3, mice received
an initial dose of 100 mg/kg CXR9 or HXR9 intratumorally.
Each treatment group contained 10 mice. The mice were
monitored carefully for signs of distress, including behavioral
changes and weight loss.
Statistical analysis
All data were presented as mean values6 standard errors
(SE). Unless otherwise stated, results were representative of at
least three independent experiments. Statistical analysis was
performed using the t-test with p< 0.05 deemed statistically
signiﬁcant. p Values relative to HXR9-treated cells were
always referred to CXR9-treated cells.
Results
HOXB7 and HOX cofactor expression in melanoma cell
lines
We previously reported the constitutive expression of
HOXB7 in both melanoma primary lesions and cell lines.8
Here we have conﬁrmed and extended the expression pattern
of HOXB7 performing qRT-PCR and western blot analyses
on normal human epidermal melanocytes from foreskin and
on a panel of melanoma cell lines derived from tumors at
different stages of progression (Figs.1a and 1b) (Supporting
Information Table S1). Although we found HOXB7 mRNA
expression in melanocytes and in all the analyzed melanomas
(Fig. 1a), HOXB7 protein showed a statistically signiﬁcant
higher expression in melanoma cell lines compared to the
normal counterpart (Fig. 1b). In view of the requirement of
HOX cofactors, such as PBX proteins, for HOXB7 oncogenic
activity,9 we measured the levels of PBX1 and PBX2 proteins
in melanoma cell lines, representative of early and advanced
stages, showing that PBX2 protein was more abundant than
PBX1 (Fig. 1c, bottom). The analysis of the PBX family
mRNAs (PBX1 to 4) in the metastatic melanoma cell line
A375M conﬁrmed PBX2 principal expression (Fig. 1c, top).
Finally, western blot analysis showed a signiﬁcant higher level
of PBX2 in melanoma cell lines respect to normal melano-
cytes (Fig. 1d).
The HOXB7/PBX2 complex regulates miR-221&222
transcription
It is well known that the interaction between HOX proteins
and their PBX cofactors is dependent on a short stretch of
highly conserved amino acids in the amino terminal of the
HOX protein, identiﬁed as the hexapeptide sequence.10,11 Here
we investigated whether a direct HOXB7/PBX2 interaction
does exist and if this heterodimeric binding is functionally
required for melanoma induction and/or progression. To this
end, the putative HOXB7/PBX2 complex was co-immunopreci-
pitated by using an anti-HOXB7 speciﬁc antibody and there-
after evaluated by western blot with an anti-PBX2. As shown
in Figure 2a, results conﬁrmed the existence of HOXB7/PBX2
heterodimers in the A375M metastatic cell line.
Previous microRNA expression proﬁles, conﬁrmed by
qRT-PCR analysis, had shown that HOXB7 retroviral trans-
duction was sufﬁcient to induce miR-221 and -222 up to
three and ﬁve-fold, respectively, in a model of SkBr3
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mammary carcinoma cell line (our unpublished results). The
increase of both microRNAs upon HOXB7 expression in these
cells prompted us to look for the possible involvement of
HOXB7 and PBX2 in miR-221&222 positive regulation. To
demonstrate that the HOXB7/PBX2 dimer can activate the
transcription of miR-221&222 in melanoma, we selected the
Me1402/R cell line for HOXB7 transient over-expression (Fig.
2b, right). qRT-PCR analysis demonstrated that 48 hr after
transfection, the endogenous levels of miR-221 and miR-222
displayed a small, but consistent 20 to 30% increase as com-
pared with empty vector (pSG5)-transfected control cells (Fig.
2c, right). In addition, we conﬁrmed the HOXB7-dependent
induction of miR-221&222 in normal human melanocytes
lentivirally infected with HOXB7. As shown, a three-fold
induction of both microRNAs was obtained as a consequence
of HOXB7 overexpression (Figs. 2b, left and 2c, left).
The speciﬁcity of this HOXB7/PBX2-dependent activation
was further sustained by miR-221&222 downregulation when
HOXB7 or PBX2 were knocked-down. Results were always
obtained by comparing Dsi-HOXB7 or Dsi-PBX2-treated
cells with Dsi-scrambled (Dsi-scr) and/or untreated controls
(Fig. 2d and Supporting Information Fig. S1a). In order to
understand the molecular bases of HOXB7 action on the
regulation of these microRNAs, we looked for HOX/PBX
binding sites (BS) in the 1.8 kb sequence upstream to pre-
miR-221&222. Bioinformatic analysis using MatInspector
Figure 1. Expression analysis of HOXB7 and PBX2 in normal human melanocytes and melanoma cell lines. (a) qRT-PCR and (b) Western blot
(WB) analyses of HOXB7 with relative densitometric evaluation. (c) qRT-PCR of PBX-1 to -4 evaluated in the A375M melanoma cell line
(top), WB analysis of PBX1 and PBX2 in melanocytes and some representative melanoma cell lines (bottom). (d) WB and relative densito-
metric analysis of PBX2. GAPDH and actin are the internal controls. **p<0.001.
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Figure 2. The HOXB7/PBX2 complex up-regulates miR-221&222. (a) Coimmunopreciptation analysis of PBX2 and HOXB7 in A375M cell
lysates. Proteins were immunoprecipitated with the HOXB7 Ab and immunoblotted with HOXB7 and PBX2 Abs. (b) WB analysis of HOXB7
enforced expression in normal human melanocytes and in Me1402/R melanoma cell line. LXSN and pSG5 are the empty vector controls. (c)
qRT-PCR of miR-221&222 normalized on RNU6B in the same cells as in (b). (d) qRT-PCR evaluation of HOXB7 and miR-221&222 in Dsi-
HOXB7-transfected A375M (left) and Me1007 (right) cell lines. (e) Schematic depiction of the genomic region upstream to pre–miR-
221&222. BS1 and BS2 indicate the HOX/PBX binding sites. (f) WB analysis of endogenous HOXB7 and PBX2. (g) Promoter luciferase
assays performed in the 293FT and A375M cells transfected with either HOXB7 expressing vector or a Dsi-HOXB7. As controls, empty vec-
tor, Dsi-scrambled and mutated binding sites were included. (h) Chromatin immunoprecipitation assay performed in A375M cells and sub-
sequently analyzed by semiquantitative PCR. GAPDH and RNU6B were used for normalization. *p<0.05. **p<0.01. mut, mutated.
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software (http://www.genomatix.de) indicated the presence of
two canonical HOX/PBX consensus sequences (TAAT/TGAT)
located in the promoter region at position 2255 and 21390
(Fig. 2e). To test whether these putative BSs were truly func-
tional, we performed a series of promoter luciferase assays by
utilizing the highly transfectable 293FT and the metastatic mela-
noma A375M cell lines, endogenously expressing both HOXB7
and PBX2 (Fig. 2f). Sequences comprised between 21786 and
11 nt and containing the HOX/PBX BSs were cloned in a pro-
moter-less pGL vector and cotransfected with either a HOXB7-
containing expression vector or a Dsi-HOXB7. In the presence
of the genomic fragments (2352/11) or (21786/21035),
HOXB7 induced a 30% increase, whereas its silencing produced
a 40% decrease of the luciferase activity, thus indicating a
HOXB7-dependent transcription. Furthermore, point mutations,
inserted in the core binding sequences for HOX/PBX, restored
luciferase to the background levels, demonstrating that the bind-
ing sites identiﬁed were speciﬁcally responsible for most of the
HOXB7-induced activation (Fig. 2g).
Finally, we demonstrated by chromatin immunoprecipita-
tion (ChIP) assays in the A375M cells the in vivo direct
interaction of HOXB7 and PBX2 proteins with the putative
cis-regulatory elements present on miR-221&222 promoter:
PCR ampliﬁcations of unsheared input genomic DNA, anti-
HOXB7 or anti-PBX2 antibody-mediated reactions revealed a
signiﬁcant HOXB7 and PBX2 binding to these BSs (BS1 and
BS2) compared with a negative control obtained by immuno-
precipitation with an irrelevant antibody (Fig. 2h).
MiR-221&222 directly target c-FOS.
The upregulation of c-FOS has been reported as a key event
in apoptosis induction in cancer cells.12 We here searched for
the option of a miR-221&222 dependent regulation of c-FOS.
Basing on bioinformatics analyses (www.targetscan.com),
we found the presence of one conserved binding site for
miR-221&222 in the 3’UTR of the c-FOS transcription factor
(Fig. 3a). The negative regulation of c-FOS by miR-221&222
was conﬁrmed by western blot analysis in miR-221&222-
transduced Me1007 and Me1402/R melanoma cell lines (Fig.
3b, left). Notably, the opposite expression pattern was
observed in the antagomiR-treated A375M and Me665/1
metastatic melanoma cell lines, where a signiﬁcant induction
of c-FOS was obtained by miR-221 and/or -222 abrogation
(Fig. 3b, right). It is important to note that miR-221 and
miR-222 appear to equally contribute to c-FOS regulation.
To verify that c-FOS was directly targeted by miR-221&222,
the 3’UTR region of c-FOS, containing either wild type or
mutated miR-221&222 binding sequences, was cloned down-
stream to the luciferase open reading frame. The presence of
wild-type ‘‘seed’’ caused a 40% and 50% inhibition of the lu-
ciferase activity in presence of cotransfected miR-221 and
-222, respectively. In contrast, the luciferase level of the
mutated 3’UTR was unaffected by both miRs, thus conﬁrm-
ing the speciﬁcity of miR-221&222 dependent targeting of
c-FOS (Fig. 3c).
We then assessed the inverse correlation of miR-221&222
and c-FOS expressions by comparing their endogenous levels
in normal melanocytes and melanoma cell lines. As
miR-221&222 expressions are directly related with melanoma
progression, being almost undetectable in normal human me-
lanocytes and increasingly expressed throughout transforma-
tion process (Supporting Information Fig. S3a), c-FOS was
expected to decline from primary to metastatic melanoma.
Nonetheless at ﬁrst sight the expression results did not show
a clear opposite pattern of miR-221&222 and c-FOS (Fig. 3d),
thus suggesting a more complex regulation. C-FOS is known
to be stabilized by phosphorylation at serines 362 and 374
upon ERK1/2 activation downstream to the MAPK pathway,
which is constitutively activated in most melanomas.22–24
Phospho-FOS (PS374-FOS) and c-FOS evaluation by western
blot conﬁrmed their variable levels, thus supporting the com-
plex relationship between miR-221&222 expression levels and
c-FOS phosphorylation and stability (Fig. 3d). Considering
that metastatic melanomas are frequently characterized by
BRAF V600E heterozygous mutation,25 we assessed its role on
c-FOS stability by transiently transfecting BRAF V600E in the
early primary Me1007 cell line, endogenously expressing wild-
type BRAF. After transfection, we observed ERK1/2 activa-
tion, PS374-FOS induction and, as a consequence of this stabi-
lizing phosphorylation, higher c-FOS levels with respect to
the control (Fig. 3e). In view of this multifaceted regulation,
the reduced expression of c-FOS detected in metastatic mela-
nomas could rely on a balance between c-FOS stability and
the high levels of miR-221&222.18
HXR9 induces apoptosis in metastatic melanoma in vitro
and in vivo
To further conﬁrm the activating function of the HOXB7/
PBX2 complex, we took advantage of the peptide HXR9.
This designed peptide is a competitive inhibitor of the HOX/
PBX dimerization which disrupts their interaction by mim-
icking the highly conserved hexapeptide in the HOX pro-
tein.12 In all the experiments, as an irrelevant control, we
utilized CXR9, a peptide lacking the functional PBX binding
site through a single amino acid substitution.
At ﬁrst we performed a series of experiments to conﬁrm
the HXR9 antineoplastic functions in a number of human
melanoma cell lines. Looking for HXR9 cytotoxicity, the
MTS assay revealed that HXR9 inhibited Mel888, Me1007
and A375M cell growth with IC50s of 48, 30 and 10 mM,
respectively, whilst the CXR9 control peptide had no discern-
ible effects (Fig. 4a).
To evaluate the potential pro-apoptotic effects of HXR9,
we used the propidium iodide staining checking for the sub-
G0 accumulation of cells. Treatments of Mel888, Me1007
and A375M cells with different HXR9 concentrations (prop-
erly ranging from 5 to 120 mM, according to the each differ-
ent IC50) resulted in a marked dose dependent increase of
the sub-G0 population (Supporting Information Fig. S2). By
comparing the results obtained with the 40 mM dose, we
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observed a HXR9 signiﬁcant induction of apoptosis in all the
treated cell lines, with a maximum of 63.2% in the A375M
metastatic cell line (Fig. 4b). In order to see whether HXR9
would also induce apoptosis in normal cells, we performed
both ﬂow cytometry of sub-G0 cells and annexin V and
7AAD staining analyses on a population of normal human
melanocytes. Interestingly, HXR9-treated melanocytes did not
undergo any form of cell death, revealing absence of cyto-
toxic effects in non-tumorigenic cells (Fig. 4c).
To establish whether the cells where actually dying
through an apoptotic pathway, we applied a direct assay for
caspase-3 activity, an early indicator of apoptosis, using a ﬂu-
orescently labeled caspase-3 substrate. HXR9 treatment
resulted in a marked activation of caspase-3 in A375M and
Mel888 cell lines when compared with untreated and CXR9-
treated cells (Fig. 4d, top). A speciﬁc aldehyde inhibitor was
utilized to conﬁrm the speciﬁcity of ﬂuorescence emission as
a result of caspase-3 activity. In addition, western blot analy-
sis showed a decreased amount of pro-caspase-7 as well as an
increase of the active proteolytic fragment in HXR9-treated
A375M versus controls (Fig. 4d, bottom). The A375M cells
treated with the pan-caspase inhibitor z-VAD-fmk before
HXR9 treatment, showed a 25% of protection from a HXR9-
induced cell death (data not shown).
In order to evaluate whether HXR9 might be able to block
melanoma cell growth also in vivo, we subcutaneously
injected into athymic nude mice the A375M cells. Once
tumors had reached 100 mm3, mice received a single intratu-
mor dose of HXR9 or CXR9 and tumor growths were fol-
lowed and compared over approximately 3 weeks. As shown
(Fig. 4e), HXR9-treated tumors showed a signiﬁcant degree
of growth retardation compared to the control groups.
HXR9 blocks the HOXB7/PBX2-miR-221&222-c-FOS
pathway
The competence of the HOXB7/PBX2-miR-221&222-c-FOS
pathway was then veriﬁed in presence of either the HXR9 or
the CXR9 peptides. The A375M cell line treated with the
Figure 3. c-FOS targeting by miR-221&222. (a) Nucleotide pairing between the c-FOS 3’UTR and miR-221&222 is shown by bars. In the seed
sequence (bold font), mutated nucleotides are shown as mismatched. (b) Representative WB analysis of c-FOS in Me1007 and Me1402/R
control (Tween vector) versus miR-221- or 222-infected cells (left) and antagomiR-221 and/or 222-transfected A375M and Me665/1 mela-
noma cells (right); antagomiR-133a represents a negative control. (c) Luciferase (LUC) reporter assay performed by cotransfecting miR-221
and=or miR-222 in the presence of the LUC reporter gene linked to c-FOS 3’UTR. As controls, mutated 3’UTR sequences and a non-targeting
oligomer were also included. Representative WB of (d) PSer374-FOS (P-FOS) and c-FOS in normal human melanocytes and melanoma cell lines
and (e) P-FOS, c-FOS, P-ERK1/2 and total ERK1/2 in BRAFV600E-transfected Me1007 cell line. **p<0.01. mut, mutated.
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Figure 4. Toxicity and cell death evaluation after HXR9 treatment. (a) Viability of Mel888, Me1007 and A375M cells assessed with the MTS
assay. The resulting IC50s were 49 mM, 30 mM and 10 mM, respectively. (b) Representative apoptosis analysis of (b) PI-sub-G0 stained popu-
lation of CXR9-or HXR9-treated melanoma cell lines and (c) PI-sub-G0 (top) or annexin V-FITC and 7AAD-A staining (bottom) of normal
human melanocytes. (d) Detection of caspase-3 activity in Mel888 and A375M cells (top). Reversible aldehyde inhibitor was included as a
control. WB of pro-caspase-7 and active caspase-7 in A375M (bottom). The longer exposure evidences the active form of caspase-7. (e) In
vivo tumor growth into athymic nude mice of A375M derived tumor nodules either untreated or intratumorally treated with HXR9 or CXR9.
*p<0.05, **p<0.01, ***p<0.001.
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HXR9 peptide was then analysed by co-immunoprecipitation
and ChIP. The HXR9 treatment totally abrogated the
HOXB7 binding with PBX2 and, in turn, with DNA, endors-
ing the higher afﬁnity of the HOX/PBX complexes for DNA
(Figs. 5a and 5b). Co-immunoprecipitation studies, per-
formed with the anti-HOXB7 antibody, allowed the recovery
of PBX2 in untreated and CXR9, but not in HXR9-treated
cells, conﬁrming that HXR9 does indeed block the interaction
between PBX2 and HOXB7 (Fig. 5a). Accordingly, chromatin
immunoprecipitation (ChIP) assays in the A375M metastatic
cells treated with the HXR9 peptide totally abrogated the
HOXB7 or PBX2 binding to the analyzed BS1 and BS2. As a
negative control we also run this immunoprecipitation with
an unrelated irrelevant antibody (Fig. 5b and Supporting In-
formation Fig. S1b). In addition the speciﬁcity of our results
and the absence of other HOX/PBX binding sites was con-
ﬁrmed through the analysis of two negative control regions,
(2891/2698) and (21066/2902) (Supporting Information
Fig. S1c).
Unexpectedly, the analysis of HOXB7 and PBX2, eval-
uated by western blot of total cell lysates kept apart before
immunoprecipitation, showed a HXR9-dependent decrease of
both HOXB7 and PBX2 expression levels (Fig. 5c). As the
qRT-PCR analysis performed on Mel888 and A375M cell
lines, as representative primary and metastatic melanomas,
did not show any signiﬁcant modulation of both mRNAs in
response to HXR9 (Fig. 5d), we hypothesized a post-tran-
scriptional regulation of HOXB7 as well as PBX2. Speciﬁcally,
we looked for the option of HOX/PBX dimers being more
stable than monomers. To this end, we silenced either
HOXB7 or PBX2 in the A375M cells, in turn adding the pro-
tein synthesis inhibitor cycloheximide (CHX) in the differ-
ently silenced cells (i.e. Dsi-scr, Dsi-HOXB7, Dsi-PBX2).
Interestingly, a reciprocal shortening of the protein half-lives
was clearly visible either in Dsi-HOXB7- or Dsi-PBX2-trans-
fected cells (i.e. HOXB7 downregulation in Dsi-PBX2 trans-
fected cells and viceversa) (Fig. 5e and Supporting
Information Fig. S1d).
Notably, treatment of both Mel888 and A375M with the
HXR9 peptide also led to a clear down-regulation of both
miR-221 and -222 in comparison with CXR9-treated cells
(Fig. 5f), once again conﬁrming the higher afﬁnity of the
HOXB7/PBX2 complex for DNA and their requirement for
miR-221&222 transcription.
In view of this signaling, we tried to determine whether
miR-221&222 per se were involved in the apoptotic process.
As we already reported18 and extended here, miR-221&222
are gradually upregulated during melanoma progression and
their expression levels associated with increased proliferation
(Supporting Information Fig. S3). We then selected the
A375M metastatic cell line for evaluating the functional
effects deriving from miR-221&222 inhibitions by transfect-
ing the antagomiR-221 and/or -222 molecules. The evalua-
tion of the percentage of apoptotic cells by cytoﬂuorimetric
analysis of propidium iodide incorporation and Annexin V
binding revealed an increase of 15% in cell death in treated
cells with respect to cells either untreated or treated with an
unrelated antagomiR (i.e., the antisense sequence targeting
miR-133a, whose expression is totally absent in melanoma,
our unpublished result) (Fig. 5g, left). The speciﬁcity of the
down-regulation of these two miRs was conﬁrmed by qRT-
PCR (Fig. 5g, right).
As qRT-PCR (Fig. 6a, left) and western blot analyses (Fig.
6a, right) conﬁrmed c-FOS induction in HXR9-treated mela-
noma cells, we tested whether this up-regulation might be
directly responsible for the HXR9-mediated apoptosis.
A375M cells were transfected with a siRNA speciﬁcally tar-
geting c-FOS mRNA (siFOS) prior to HXR9 treatment. A
second non-targeting siRNA was used as a control (contr)
and real-time qRT-PCR analysis conﬁrmed the speciﬁc
down-regulation of c-FOS (Fig. 6b). This reduction resulted
in a signiﬁcant protection from HXR9-induced cell death as
shown by the increased percentage of surviving cells (from
10 to 65%) in presence of siFOS (Fig. 6c).
To deﬁnitely support the existence of a link among
HOXB7, PBX2 and c-FOS, we analyzed c-FOS mRNA in Dsi-
RNA-mediated silencing of either HOXB7 or PBX2: a statisti-
cally signiﬁcant induction of c-FOS (approximately 2.5- and
1.5-fold) was obtained in both silenced conditions compared
with control A375M cells (Fig. 6d and Supporting Informa-
tion Fig. S1e). Accordingly, HOXB7 overexpression induced a
decrease of c-FOS level (Fig. 6e).
As the c-FOS/c-JUN heterodimers have been shown to
repress the antiapoptotic molecule c-FLIP(L),26 we decided to
compare also c-JUN and c-FLIP(L) protein levels in
untreated, CXR9- or HXR9-treated A375M. We did not
observe any c-JUN modulation, whereas the c-FLIP(L) pro-
tein level was reduced in HXR9-treated cells (Fig. 6f). In
addition, western blot analysis of the tumor suppressor pro-
tein PTEN, reported as an additional target of miR-221&222
in NSCLC,17 did not show any signiﬁcant modulation after
HXR9 treatment in melanoma cells (Fig. 6f).
Expression studies obtained by qRT-PCR on day 21 tumor
nodules, conﬁrmed a HXR9-based down-regulation of miR-
221 and -222 followed by c-FOS restored expression also in
vivo (Fig. 6g), further supporting the option of c-FOS as a
direct target of miR-221&222.
Finally, the effectiveness of this regulatory pathway was
assessed in bioptic samples from patients by immunohysto-
chemistry for HOXB7 and c-FOS (Supporting Information
Fig. S4a) and in situ hybridization for miR-221&222 (Sup-
porting Information Fig. S4b). Results conﬁrmed lower
HOXB7 and higher c-FOS in primary respect to advanced
melanomas (Supporting Information Fig. S4a). Accordingly,
miR-221&222 direct and inverse correlations with HOXB7
and c-FOS are shown (Supporting Information Fig. S4b).
Discussion
Melanoma is an aggressive malignancy, the incidence of
which is increasing very rapidly worldwide. Although it is a
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Figure 5. HXR9-dependent effects in A375M and Mel 888 melanomas. (a) Coimmunoprecipitation and (b) Chromatin immunoprecipitation
assays performed in A375M cells treated with 40 mmol/L of HXR9 or CXR9. (c) WB analysis of PBX2 and HOXB7 in total cell lysates kept
apart before co-immunoprecipitation. (d) qRT-PCR analysis of HOXB7 and PBX2 levels in A375M and Mel888 melanoma cell lines. (e)
A375M cells transfected with either control Dsi-scr, or with Dsi-HOXB7 and treated with cycloheximide (CHX). HOXB7, PBX2 and actin pro-
tein levels were evaluated at the indicated time points. (f) Evaluation of miR-221 and miR-222 levels by qRT-PCR in HXR9-treated A375M
and Mel 888 cells compared with CXR9 controls. (g) Flow cytometric evaluation of apoptotic cells in antagomiR-treated A375M cells (left);
miR-221&222 reduction confirmed by qRT-PCR (right). Actin, RNU6B and GAPDH were used as internal controls. AntagomiR-133a was used
as a negative control. *p<0.05, **p<0.01.
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Figure 6. c-FOS regulation in HXR9-treated cells. (a) qRT-PCR (left) and representative WB (right) of c-FOS. (b) c-FOS expression and (c) eval-
uation of cell survival in A375M cells treated with an anti-c-FOS siRNA (siFOS) or a control siRNA (contr) 24 hr before treatment with 40 mM
HXR9 or CXR9. Evaluation of c-FOS level by qRT-PCR in (d) A375M and Me1007 cells after HOXB7 silencing and in (e) HOXB7-overexpressing
normal human melanocytes and Me1402/R melanoma cell line. LXSN and pSG5 are the empty vector controls. (f) Representative WB of c-
FLIP, c-JUN and PTEN in the A375M melanoma cell line treated with 40 lM CXR9 or HXR9. Actin was the internal loading control. (g) qRT-
PCR of miR-221, miR-222 and c-FOS in RNAs extracted from tumors recovered from mice 21 days after s.c. injection of A375M melanoma
cells. Actin, RNU6B and GAPDH were used for normalization. *p<0.05, **p <0.01, ***p<0.001.
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highly curable disease in its early stages, advanced diseases
lack effective treatments.1 An improved understanding of the
underlying mechanisms is important in order to identify
novel therapeutic targets.
Homeobox (HOX)-containing genes represent a subset of
transcription factors involved in normal development and
organogenesis.3 HOX gene clusters are a paradigm of genetic
redundancy deriving from genome duplications. Nonetheless
HOX proteins display a high regulatory speciﬁcity possibly
through their cooperation with cofactors and other transcrip-
tion factors.9 In melanoma we demonstrated that HOXB7
participates in the autocrine regulation of bFGF through
direct transactivation. HOXB7 expression appeared tightly
regulated in normal human melanocytes and constitutively
activated in melanomas.8 In addition Wu and coauthors
demonstrated that breast cancer cell lines, transfected with
HOXB7 start to display many features related to EMT, such
as loss of expression of adhesion molecules and changes in
cell morphology and cytoskeletal arrangement.27 Concord-
antly, other recent ﬁndings suggested HOXB7 could be a val-
uable prognostic factor in colorectal cancer28 and oral
squamous cell carcinoma.29
Our previous studies also demonstrated the requirement
of Three Amino acid Loop Extension (TALE) cofactors for
HOXB7 associated oncogenesis and the ability of HOXB7 to
regulate this class of molecules, increasing the expression of
PBX2 and reducing that of PBX1.9 Consistently, we showed
that the SkBr3 breast carcinoma cell line, upon transduction
of HOXB7, became positive for bFGF acquiring a more
malignant phenotype.8 In the same cells we found a HOXB7-
dependent induction of several proliferative and pro-angio-
genic molecules such as VEGF, GROa, ANG-2 and IL-8.7 In
this study we have shown that there is a striking HOXB7-
dependent upregulation of miR-221&222, whose tumorigenic
functions have been described in several type of cancer.18,30,31
In particular, in melanoma they enhance tumorigenicity by
targeting, among many other molecules, p27Kip1, ETS-1 and
c-KIT receptor, thus leading to enhanced proliferation, dis-
semination and differentiation blockade of melanoma
cells.18,21
Few data do exist on microRNA transcriptional regulation.
For miR-221&222, we had already identiﬁed the promyelo-
cytic leukemia zinc ﬁnger (PLZF), previously reported as a
tumor suppressor down-modulated in melanomas,32 as an
upstream negative regulator of miR-221 and miR-222. In
addition, we demonstrated a miR-221&222/ETS1 circuitry
where ETS1, besides being targeted by miR-222, plays a tran-
scriptional activating role on miR-221&222 according to its
ERK-dependent phosphorylation status.21 Here we show that
the HOXB7/PBX2 complex is a direct transcriptional activa-
tor of miR-221&222. By using HXR9, an antagonist of HOX/
PBX dimer formation, we conﬁrmed the requirement of these
complexes for effective binding to DNA and transcription.
HXR9 treatment results in the downregulation of miR-
221&222 in human melanoma cells as a consequence of
HOXB7/PBX2 heterodimer disruption and the subsequent
degradation of HOXB7 and PBX2 proteins. This apparent
instability of HOX and PBX monomers may reﬂect a regu-
latory mechanism similar to that reported for the C/EBP
family of proteins, whereby monomers are degraded to
avoid any intracellular unbalance, and the proteins are sta-
bilized by either homo- or heterodimerization.33 Results
reporting treatments with the proteasome inhibitor MG132
showed a cytoplasmic accumulation of PBX2, suggesting
that its degradation goes through the proteasome, particu-
larly when it is in a monomeric excess over its partners.34
Also a Mass Spectrometry analysis, performed on human
lung adenocarcinoma cells (H1299), suggested HOXB7 as a
substrate of the ubiquitination machinery.35 In melanoma
cells HOXB7 silencing conﬁrmed the lower stability of
PBX2 when the lack of its partner hampers a correct dime-
rization and vice versa (Fig. 5e and Supporting Information
Fig. S1d).
In this study we have identiﬁed c-FOS as an additional
target of miR-221&222 in melanoma, describing the func-
tionality of a HOX/PBX!miR-221&222!c-FOS pathway.
C-FOS, together with c-JUN, is part of the activator protein-
1 (AP-1), a complex able to exert either pro- or anti-apopto-
tic functions in different cell populations, including tumor
cells.36 Increased c-FOS has been associated with apoptosis in
different cell types subjected to various treatments,12–15
including TRAIL-induced apoptosis through c-FLIP(L)
repression in prostate cancer.26,37 As previously reported by
Croce and collaborators for non-small cell lung cancer
(NSCLC), c-JUN, but not c-FOS, is able to transactivate miR-
221&222 by direct binding to their promoter region.16 In
HXR9-induced apoptosis in melanoma, we found miR-
221&222 downregulation directly associated with c-FOS up-
regulation, thus conﬁrming the speciﬁcity of miR-221&222/c-
FOS, with no effects on the other member of the AP-1 com-
plex. We also reported the lack of any evident involvement
of PTEN in HXR9-induced apoptosis. Although PTEN has
been validated as a miR-221&222-dependent target in HCC
and NSCLC,17 it does not seem to exert this function in
HXR9-treated melanomas, thus strengthening the key role of
c-FOS in inducing apoptosis.
Surprisingly, the analysis of miR-221&222 and c-FOS lev-
els in the panel of melanoma cell lines did not reveal the
expected obvious inverse correlation between microRNAs
and their targets (Fig. 3d). However, c-FOS protein is stabi-
lized by post-translational modiﬁcations, such as phosphoryl-
ation at serines 362 and 374,22–24 whose levels are directly
related with the activation of the MAPK pathway.38 In view
of that, c-FOS levels in the analyzed cell lines, besides being
regulated by miR-221&222, are dependent upon the phos-
phorylation status of ERK1=2, as suggested for the NGF-de-
pendent cell survival in PC12 cells.39 This might explain the
low level of c-FOS detectable in primary melanomas (as
Mel501 and Me1007) lacking any of the frequent mutations
in B-RAF or N-RAS genes. These melanomas, although
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expressing low levels of miR-221&222, display a small
amount of c-FOS according to its barely phosphorylated sta-
tus. Accordingly, BRAFV600E transfection in Me1007 mela-
noma induced a striking ERK1/2 activation followed by
c-FOS induction (Fig. 3e). Thus, the reduced expression of
c-FOS in metastatic melanomas would be expected to depend
upon the repressive function of miR-221&222 which appear
to overcome c-FOS stability.18 It is ﬁnally important to point
out the extreme effectiveness of HXR9 in the induction of
apoptosis in human melanoma cells and the absence of any
HXR9-derived toxicity in the normal counterpart, here repre-
sented by primary human melanocytes. Accordingly, a lack
of any apparent toxicity has been shown in HXR9-treated
mice. In particular, no abnormalities have been detected in
hematopoietic cells, either from bone marrow or peripheral
blood, where the HOX genes are known to be highly
functional.12
Taken together, our results suggest that the direct inhibi-
tion of miR-221&222 by antagomiR treatment and/or the
disruption of the HOXB7/PBX2 dimers might represent an
innovative approach for translation into the clinical setting
(Supporting Information Fig. S5). Furthermore, as this and
other studies suggest the existence of common regulatory sig-
naling for miR-221&222 and HOXB7,18,40,41 the combined
treatments could be more effective due to a synergistic
interaction.
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